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Abstract 
Introduction 
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy in the United States 
(US). This study describes the survival of children with ALL in the US utilizing the most comprehensive 
and up-to-date cancer registry data. 
Methods 
We utilized data from 37 state cancer registries that cover approximately 80% of the US population. 
We estimated age-standardized survival up to 5 years for children aged 0-14 years diagnosed with ALL 
during two time periods: 2001-2003 and 2004-2009.  
Results 
We included 17,500 children with ALL. The pooled age-standardized net survival estimates for all US 
registries combined were 95% at 1 year, 90% at 3 years and 86% at 5 years for children diagnosed 
during 2001-2003, and 96%, 91%, and 88%, respectively, for those diagnosed during 2004-2009. Black 
children diagnosed during 2001-2003 had lower 5-year survival (84%) than white children (87%) and 
less improvement in survival by 2004-2009. For 2004-2009, 1-year and 5-year survival was 95.7% and 
88.6% for white children and 95.5% and 83.6% for black children. For 2004-2009, Survival was highest 
among children aged 1-4 years (95%) and lowest among children less than one year of age (60%). 
Discussion 
We found overall net survival from childhood ALL in the US to be high, but disparities by race still exist, 
especially beyond the first year after diagnosis. Clinical and public health strategies are needed to 
improve healthcare access, clinical trial enrollment, treatment, and survivorship care for children with 
ALL. 
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Introduction 
One of the great successes in medicine in the United States (US) has been the increasing survival of 
children with cancer. In the past 50 years, 5-year survival from all cancers combined among children in 
the US has increased from under 60% to nearly 80%
1
. Acute lymphoblastic leukemia (ALL) is the most 
common childhood malignancy worldwide, accounting for 20-30% of overall childhood cancer 
incidence.
2-5
 Before 1950, childhood ALL was uniformly fatal.
6
 In the 1960s, five-year survival for 
children with ALL in the US was less than 10%.
7,8
 Since then, five-year survival has dramatically 
improved, from 57% between 1975 and 1979 to 90% between 2003 and 2009.
2,9
 This increase in 
survival is consistent with stable incidence rates and decreasing mortality rates
10-12
. 
Progress made in childhood ALL survival in developed countries over the past four decades largely 
stems from clinical and public health-related cancer control efforts. These include increasing clinical 
trial enrollment, improved supportive care, and risk-directed therapy that optimizes the efficacy of 
existing antileukemic agents.
1,13-16
 Pediatric cancer collaborative treatment groups, which have 
reported enrollment of over two-thirds of childhood ALL cases over the past two decades, designed 
randomized clinical trials that used risk-adaptive algorithms to adjust the intensity of treatment based 
upon factors such as ALL subtype and chromosomal changes, age and white blood count on diagnosis, 
presence of disease in the central nervous system, and persistence of residual disease during 
treatment.
8,13,17-19
 In addition to improving relapse-free and overall survival, a risk-based approach has 
allowed clinicians to reduce toxicities that contribute to late complications and mortality.
17
  
Clinical trials and ensuing advances in risk-based therapy have contributed to the remarkable progress 
in improving clinical outcomes in the US and other countries.
13,14,20
 This success lies in contrast to five-
year survival of less than 40% in many developing countries, which largely results from abandonment 
of therapy and high treatment-related mortality.
21-23
 Five-year net survival for children diagnosed with 
ALL has been previously estimated above 85% in the US, while it was still below 50% in several less 
wealthy countries participating in the worldwide cancer survival comparison of the CONCORD-2 
study.
2,9
 The CONCORD-2 study established worldwide surveillance of cancer survival in 67 countries 
using data from over 25 million persons diagnosed with cancer from 279 cancer registries.
9
 This study 
builds upon the CONCORD-2 study and describes the survival of children with ALL in the US utilizing the 
most comprehensive and up-to-date cancer registry data available by race and age. 
 
Methods 
We used data from 37 state-wide cancer registries that participated in the CONCORD-2 study, covering 
approximately 80% of the US population, and consented to inclusion of their data in the more detailed 
analyses reported here
9
. We analysed individual records for 17,500 children (0-14 years) diagnosed 
with precursor-cell acute lymphoblastic leukemia (ICD-O-3
24
 morphology codes 9727-9729; 9835-9837) 
during 2001-2009 and followed up to December 31, 2009. We included all children with ALL in the 
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analyses, even if the child had had a previous malignancy. In the extremely rare instance that a child 
was diagnosed with ALL on two or more occasions during 2001-2009, only the first occurrence was 
considered in the survival analyses. 
We estimated net survival up to 5 years, with 95% confidence intervals (CI), for children diagnosed 
during 2001-2003 and 2004-2009, by race and state. We used the Pohar Perme estimator
25
 of net 
survival. Net survival can be interpreted as the probability of survival up to a given time since diagnosis, 
after controlling for other causes of death (background mortality). To control for differences in 
background mortality between participating states, by race and over time, we constructed life tables of 
all-cause mortality in the general population of each state from the number of deaths and the 
population, by single year of age, sex, calendar year and, where possible, by race (black, white), using a 
flexible Poisson model.
26
 The life tables have been published.
27
 
Children were grouped by diagnosis year into two calendar periods (2001-2003 and 2004-2009) to 
reflect changes in the methods used by US cancer registries to collect data on stage at diagnosis. From 
2001-2003, most registries coded stage directly from medical records to Surveillance, Epidemiology, 
and End Results Summary Stage 2000.
10
 Since 2004, all registries have derived Summary Stage 2000 
using the Collaborative Staging System.
11
  
We estimated net survival using the cohort approach for patients diagnosed in 2001-2003, since all 
patients had been followed up for at least five years by December 31, 2009. We used the complete 
approach to estimate five-year net survival for patients diagnosed during 2004-09, because five years 
of follow-up data were not available for all patients. Net survival was estimated for three age groups 
(0–4, 5–9 and 10–14 years). We obtained age-standardized estimates by assigning equal weights to the 
three age-specific estimates.
28
 If two of the three age-specific estimates could not be obtained, we 
present only the pooled, unstandardized survival estimate for all age groups 0-14 years combined. 
Unstandardized estimates are italicized in Supplemental Table. To better explore the trend by age, the 
first age group was split into two subgroups. (Table 3) Trends, geographic variations and differences in 
survival by race are presented graphically in bar-charts and funnel plots.
29
 More details on data and 
methods are provided in the accompanying article [Allemani et al., 2017]. 
  
Results 
Data meeting the eligibility criteria for analyses came from 37 states comprising 80% of the total US 
population (Table 1). Of the 17,500 children with ALL, 83.7% were white, 8.9% were black and 7.4% 
were of other/unknown races. Almost all (98.5%) cases were morphologically verified (Table 1). There 
were no differences in morphological verification by race.  
Figure 1 presents a visual snapshot of the absolute change in 5-year age-standardized net survival 
between 2001-2003 and 2004-2009, by geographic region. For the US overall, there was an absolute 
increase in survival of 1.7% between those periods.  
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One-, 3- and 5-year age-standardized net survival for all races in the pooled US population represented 
in this study were 95.3% (CI: 94.6-95.9), 89.7% (CI: 88.8-90.7), and 86.4% (CI: 85.3-87.4) respectively, in 
2001-2003 and 95.7% (CI: 95.3-96.1), 90.7% (CI: 90.0-91.4), and 88.1% (CI: 87.2-88.9) in 2004-2009 
(Table 2). Despite these increases in survival, disparities still exist between racial groups. In 2001-2003, 
5-year net survival was 86.6% (CI: 85.5-87.7) for whites but 83.8% (CI: 80.3-87.3) for blacks. During 
2004-2009, survival increased marginally for whites (88.6% (CI: 87.6-89.5) but remained the same for 
blacks 83.6% (CI: 80.6-86.6) resulting in a slight widening of the racial divergence in survival during the 
period 2001-2009. Five-year age-standardized estimates for children diagnosed during 2004-2009 
ranged from 85.2% to 98.6% in the Northeast, 81.7% to 92.2% in the South, 87.8% to 90.3% in the 
Midwest and 86.0% to 95.9% in the West (Supplementary Table 2).  
Five-year net survival for children aged <1 year, 1-4, 5-9, and 10-14 years were 60.5% (CI: 53.4-67.6), 
92.5% (CI: 91.5-93.5), 89.2% (CI: 87.7-90.8), and 79.4% (CI: 76.9-81.9),respectively,  in 2001-2003, and 
60.1% (CI: 54.5-65.7), 94.5% (CI: 93.7-95.3), 90.4% (CI: 89.0-91.8), and 81.5% (CI: 79.4-83.6) 
respectively,  in 2004-2009 (Table 3). Survival was highest among children aged 1 to 4 years and lowest 
among those less than one year of age, with a 30 percentage point difference between these two age 
groups in both time periods. Survival was consistently slightly higher in girls than boys, with the largest 
differences observed in infants under 1 year of age throughout 2001-2009. 
Funnel plots (Figure 2) display graphically the variation in survival between states and by race. 5-year 
age-standardized net survival was generally lower among black children (solid circles) than among 
white children (open circles), although net survival estimates for black children were only available for 
three states: this is due to the difficulty of constructing life tables for blacks in some states and in 
producing age-standardized estimates of net survival (see methods section). Similar patterns were 
observed during 2004-2009.  
 
Discussion 
In this manuscript, we report the most comprehensive analysis of cancer survival to date among 
children with ALL in the US, with data from 37 cancer registries covering approximately 80% of the 
national population. We found short-term survival from childhood ALL in the US to be high. For all 
participating US states combined, the pooled estimate of 1-year net survival for children diagnosed 
during 2004-2009 was 95.7% [95% CI 95.3-96.1%], while 5-year survival was 88.1% [95% CI 87.2-
88.9%]. These 5-year survival estimates from a population-based US cohort are slightly lower but still 
closely aligned with the 5-year survival estimates of 91.4% from the Children’s Oncology Group ALL 
randomized trials for a similar period (2000-2005) and the same age group
8
. Our results were also 
within the same range as most countries in Northern and Central Europe
5,9
, and close to those in 
Canada (90.6% [88.6-92.7%] for 2005-2009)
9
. Our results are consistent with stable incidence rates and 
decreasing mortality rates for childhood ALL in the US
10-12
. 
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Despite the high overall survival, there were geographic and racial disparities. One-year survival for 
children diagnosed during 2004-2009 ranged from 91.4% to 98.9% in the Northeast. Differences in five-
year survival were even larger, ranging from 81.7% to 98.6% (Supplemental Table). Racial disparities 
were larger for longer-term survival than for shorter-term survival.  
Five-year survival for black children was typically 3 to 5percentage points lower than for white children. 
Geographic differences in survival may be explained, in part, by survival differences between white and 
black children. Survival is generally lower for black children, and the proportion of black children varies 
by state. However, we found that survival for black children was similar, if not higher, to that of white 
children in some states (Supplemental Table). This suggests that the distribution of black and white 
children does not explain all of the geographic differences in survival. Although genetic polymorphisms 
may partially explain racial differences in ALL outcomes
30
, these differences are more likely to be the 
reflection of differences in socioeconomic status and access to care.
31,32
 The survival patterns by race 
we found are consistent with higher incidence rates among white children and higher mortality rates 
among black children.
10-12
  
Survival by age at diagnosis is consistent with previous data.
33
 Survival of infants diagnosed with ALL is 
markedly lower than that for any other age group, which reflects the high prevalence and mortality of 
infant ALL cases with mixed lineage leukemia gene rearrangements
1
. This population-based study 
confirms previous findings that the highest survival is found in children aged 1-4 years, with decreasing 
survival as age increases toward adolescence
33
. We also found, as previously reported,
34
 that boys 
have lower survival from ALL than girls. This gender difference was more marked in infants, for whom 
survival was the lowest, and remained in the most recent period (2004-2009).  
Five- year survival for ALL in the United States is amongst the highest in the world and it improved 
from 83.1% to 87.7% between 1995 and 2009 as reported from the CONCORD–2 Study
9
. The high 
survival may reflect, in part, the intensity of clinical investigation performed to establish the diagnosis, 
which would be expected to improve the definition of morphological type and thus the selection of the 
most appropriate treatment. One indicator of the intensity of diagnosis is the percentage of cases for 
which microscopic confirmation of the diagnosis was available. For children diagnosed with ALL during 
the period 1995-2009 covered by the CONCORD-2 study, morphologic verification was available for 
98.4% of patients among all US registries combined and ranged between 85.6% and 100% among 
participating states
9
. As reported here, morphological verification was similar among both black and 
white children diagnosed during 2001-2009. The low percentage of cases for which the diagnosis was 
based on clinical rather than pathological evidence is not likely to be the result of selective case 
ascertainment among participating cancer registries, since all the registries were certified by the North 
American Association of Central Cancer Registries as having met data quality and completeness 
standards.  
 
Clinical perspective 
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Important advances in childhood ALL survival have been achieved through both clinical and public 
health efforts. Clinical advances include improved supportive care and recognition of avenues to 
reduce the toxicity of therapy without compromising overall outcome. These advances in childhood 
ALL survival have spanned all age groups, races, and both genders.
33
 Clinicians have had increased 
success with managing frequent complications of ALL including tumor lysis syndrome, infection during 
neutropenia, thrombosis, hemorrhage, anaphylaxis, and suppression of the hypothalamic-pituitary-
adrenal axis.
35-37
 Additionally, intrathecal therapy has been increasingly used instead of cranial 
irradiation for patients with central nervous system disease, thereby reducing radiation-associated 
morbidity and mortality.
30,38
 There has been an increasing use of immunophenotyping and cytogenetic 
characterization to predict outcome and relapse, and thus to guide risk-based adjustments in 
therapy.
6,17
 Advanced genetic characterization of ALL can contribute to improved diagnostic evaluation 
and enhance clinicians’ ability to monitor the response to therapy.
17,39
 Additionally, recent genotyping 
techniques have allowed clinicians to detect germ-line differences that may predict response to 
therapy, as well as chemotherapy-related side-effects.
30
  
 
Cancer control perspective 
Many of these clinical advances have been achieved in conjunction with public health-related cancer 
control efforts, including increasing clinical trial enrollment and improving survivorship care. Much of 
the substantial improvement in survival among children with cancer is attributable to increasing clinical 
trial enrollment.
1
 Clinical trials identify the most effective treatments and allow those treatments to be 
brought to patients. Sustained efforts by comprehensive cancer control programs to support clinical 
trial enrollment for children with cancer are needed to improve survival even further for children with 
ALL. Comprehensive cancer control programs can support efforts to increase referral to and enrollment 
in existing clinical trials, increase the number of clinical trials available, and reduce regulatory barriers 
to enrollment in clinical trials.  
With survival increasing, cancer control efforts must also focus on the long-term health of childhood 
ALL survivors 
20
. Of the 14 million cancer survivors in the US, over 50,000 are survivors of childhood 
ALL
40-42
. Treatment of ALL may result in long-term health effects that may adversely affect the long-
term health of childhood cancer survivors. Survivors of childhood ALL are at increased risk for poor 
overall health, osteoporosis, growth hormone deficiency, impaired exercise capacity, cardiomyopathy, 
infertility, cataracts, short stature, neurocognitive deficits, and poor functional status
41,43-46
. 
Comprehensive cancer control programs could encourage the adoption of survivorship care plans, 
which the Institute of Medicine recommends for all cancer survivors.
47,48
 Survivorship care plans 
provide summaries of clinical treatments and help cancer survivors understand potential late effects, 
anticipatory guidance, and long-term follow-up care. Comprehensive cancer control programs could 
also support efforts to improve providers’ knowledge of established follow-up guidelines, such as the 
Children’s Oncology Group Long-Term Follow-Up Guidelines
49
. More widespread implementation of 
Page 7 of 21 Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
8 
 
these guidelines could help improve and harmonize providers’ knowledge on potential late effects, 
screening, evaluation, anticipatory guidance, counseling, and other interventions.
49
  
Additionally, comprehensive cancer control programs could encourage innovative uses of cancer 
registry data to improve cancer survivorship. Examples of effective activities include Centers for 
Disease Control and Prevention (CDC)-supported efforts to utilize existing cancer registry data to 
populate survivorship care plans
50
. Improved surveillance of late effects among cancer survivors, using 
population-based cancer registries, will become an essential approach to improve understanding of 
variations in long-term morbidity and mortality, and potentially to improve outcomes.  
Comprehensive cancer control programs can also support efforts to decrease disparities among 
children with ALL. While there were negligible differences in 1-year survival by race, we found black 
children had lower 5-year survival compared to white children. This may reflect differences in 
treatment over time and be related to socioeconomic status
51-53
. Cancer control efforts that increase 
access to care among lower socioeconomic status families may help to reduce racial discrepancies in 
treatment and outcomes.  
Limitations 
One limitation of this study is that it does not include patients aged 15 or older. Many previous reports 
have included patients aged 15-19 in an evaluation of childhood. Therefore, comparing this study to 
other studies must account for differences in study population age.
2,3,10
  
Records of children diagnosed with leukemia were selected for analysis if their ICD-O-3 morphological 
code was in the 6 codes proposed by the HAEMACARE group for ALL
54,55
.  
Despite the fact that ALL is the most common childhood malignancy worldwide, absolute case 
numbers are generally small and caution is needed in interpreting the data. Survival was estimated 
separately for each state, and estimates covering approximately 80% of the US population were also 
obtained by pooling the data from all participating states. Survival estimates could not be age-
standardized for the less populous states, because the data were sparse. This limitation applies 
particularly to comparison of survival between blacks and whites, because in most states, black 
children represent fewer than 20% of ALL cases  
Conclusions 
Survival from childhood ALL has been improving overall in 37 US states between 2001-2003 and 2004-
2009. Because of the relative rarity of childhood ALL, national and international collaboration groups 
that pool patient numbers and coordinate multi-center research efforts are essential.
13
 Continued 
collaboration will be critical in reducing health inequalities in survival from childhood ALL, as well as in 
advancing childhood ALL treatment. Similar research efforts will continue to play a central role in 
improving outcomes in other childhood cancers where survival is still well below 90%. Comprehensive 
cancer control programs can support efforts to increase clinical trial enrollment, provider’s knowledge 
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of established follow-up guidelines and encourage the use of survivorship care plans. Close monitoring 
of survivors of childhood ALL using population-based cancer registry data is essential to monitor the 
effect of the implementation of new medical and public health strategies aimed at improving survival.  
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Table 1: Acute lymphoblastic leukemia: number of children (0-14 years) diagnosed 2001-2009 and 
included in survival analysis, with quality data indicators, by US state and race 
Table 2:  Leukemia in children: age-standardized net survival (%) at 1-, 3- and 5-years for females 
diagnosed 2001-2009, by race and calendar period of diagnosis. 
NS= Net Survival 
Table 3: Acute lymphoblastic leukemia: net survival (NS,%) at 1,3,and 5 years after diagnosis for 
children (0-14years) diagnosed 2001-2009, by age, race, sex and calendar period of diagnosis: United 
States 
A: population coverage represents 80.6% of the US population in 2009 (data from the UN Population 
Division). B: Age-standardized. NS= Net Survival 
Figure 1: Acute lymphoblastic leukemia; five year age-standardized net survival(%) for children (0-14 
years) diagnosed during 2001-2003 and 2004-2009, and absolute change (%): US states grouped by 
geographic region 
US states: 37 participating states (80.6% population coverage). States are ranked within each 
geographic region by the survival estimate for 2004-2009. Dark Color- NPCR registries; pale colors- 
SEER registries. * Registries affiliated with both programs. Only age-standardized survival estimates 
were ploLed. †Change (%) not ploLed because at least one esNmate was not age-standardized 
Figure 2: Acute lymphoblastic leukemia- 5 year age-standardized net survival (%) for children (0-14 
years), by calendar period of diagnosis 
Note: Each data point represents the survival estimate for a US state, either for blacks (3 states) or 
whites (27 states) 
Supplemental Table: Acute lymphoblastic leukemia: age-standardized net survival (%) at 1,3, and 5 
years for children (0-14 years) diagnosed 2001-2009, by US state, race, and calendar period of 
diagnosis: geographic region and Census division 
Survival estimates that are not age-standardized are italicized. Dashes (-) indicate where a survival 
estimate could not be produced. NS= net survival. CI= confidence interval 
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Table 2.  Leukemia in children: age-standardized net survival (%) at 1-, 3- and 5-years for children diagnosed 2001-2009, by race and 
calendar period of diagnosis. 
 2001-2003 2004-2009 
 All races White Black All races White Black 
Years NS 
(%)  
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI NS 
(%) 
95% CI 
1 95.3 94.6 - 95.9 95.3 94.6 - 96.0 95.0 93.0 - 97.1 95.7 95.3 - 96.1 95.7 95.3 - 96.2 95.5 94.1 - 96.9 
3 89.7 88.8 - 90.7 89.8 88.8 - 90.9 87.5 84.3 - 90.6 90.7 90.0 - 91.4 91.2 90.5 - 92.0 86.7 84.2 - 89.1 
5 86.4 85.3 - 87.4 86.6 85.5 - 87.7 83.8 80.3 - 87.3 88.1 87.2 - 88.9 88.6 87.6 - 89.5 83.6 80.6 - 86.6 
 
 NS= Net Survival 
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Table 3. Acute lymphoblastic leukemia: net survival (NS, %) at 1.3.and 5 years after diagnosis for children (0-14 years) diagnosed 2001-2009, 
by age, race, sex, and calendar period of diagnosis: United States 
2001-2003 
 
Years  
All children 
 
White 
 
Black 
 
Boys 
 
Girls 
NS 
(%)  95% CI 
 
NS 
(%) 95% CI 
 
NS 
(%) 95% CI 
 
NS 
(%) 95% CI 
 
NS 
(%) 95% CI 
 
All ages 
b
 1 95.3 94.6 - 95.9 95.3 94.6 - 96.0 95.0 93.0 - 97.1 95.2 94.3 - 96.1 95.4 94.5 - 96.4 
3 89.7 88.8 - 90.7 89.8 88.8 - 90.9 87.5 84.3 - 90.6 89.1 87.8 - 90.4 90.5 89.1 - 91.9 
5 86.4 85.3 - 87.4 86.6 85.5 - 87.7 83.8 80.3 - 87.3 85.4 83.9 - 86.8 87.7 86.1 - 89.2 
<1 year 1 76.8 70.7 - 83.0   76.7 70.1 - 83.4   55.0 27.2 - 82.8   73.1 63.1 - 83.0   79.6 71.9 - 87.3 
  3 63.3 56.2 - 70.3   64.1 56.6 - 71.6   46.0 18.3 - 73.8   60.2 49.2 - 71.1   65.5 56.4 - 74.6 
  5 60.5 53.4 - 67.6   60.9 53.2 - 68.6   46.0 18.3 - 73.8   56.3 45.2 - 67.4   63.6 54.4 - 72.8 
1-4 years 1 97.9 97.4 - 98.5 97.9 97.3 - 98.5 98.4 96.5 - 100.0 98.3 97.7 - 99.0 97.5 96.6 - 98.4 
3 94.9 94.0 - 95.7 94.8 93.9 - 95.7 94.5 91.0 - 97.9 94.6 93.5 - 95.8 95.2 93.9 - 96.4 
5 92.5 91.5 - 93.5 92.3 91.2 - 93.4 93.3 89.6 - 97.1 92.3 90.9 - 93.6 92.8 91.3 - 94.3 
5-9 years 1 96.4 95.5 - 97.4   96.6 95.6 - 97.6   96.1 92.8 - 99.5   96.1 94.7 - 97.4   96.8 95.6 - 98.1 
  3 92.3 91.0 - 93.6   92.6 91.1 - 94.0   89.2 83.9 - 94.6   91.3 89.4 - 93.2   93.4 91.6 - 95.2 
  5 89.2 87.7 - 90.8   89.7 88.0 - 91.4   86.1 80.2 - 92.1   87.7 85.5 - 90.0   90.9 88.8 - 93.0 
10-14 years 1 92.8 91.3 - 94.4 92.9 91.1 - 94.6 93.1 88.8 - 97.5 92.4 90.2 - 94.5 93.5 91.1 - 95.8 
3 84.0 81.8 - 86.3 84.1 81.6 - 86.6 81.7 75.0 - 88.3 83.1 80.1 - 86.1 85.3 82.0 - 88.7 
5 79.4 76.9 - 81.9 79.8 77.1 - 82.5 74.7 67.2 - 82.2 77.9 74.5 - 81.2 81.6 77.9 - 85.3 
2004-2009 
 
Years  
All races 
 
White 
 
Black 
 
Boys 
 
Girls 
NS 
(%) 95% CI 
 
NS 
(%) 95% CI 
 
NS 
(%) 95% CI 
 
NS 
(%) 95% CI 
 
NS 
(%) 95% CI 
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All ages 
b
 1 95.7 95.3 - 96.1 95.7 95.3 - 96.2 95.5 94.1 - 96.9 95.9 95.3 - 96.4 95.5 94.8 - 96.2 
3 90.7 90.0 - 91.4 91.2 90.5 - 92.0 86.7 84.2 - 89.1 90.2 89.3 - 91.2 91.3 90.2 - 92.3 
5 88.1 87.2 - 88.9 88.6 87.6 - 89.5 83.6 80.6 - 86.6 87.4 86.2 - 88.6 88.9 87.6 - 90.2 
<1 year 1 80.5 76.4 - 84.6   78.0 73.2 - 82.8   94.9 88.7 - 100.0   78.5 72.6 - 84.3   82.8 77.1 - 88.4 
  3 61.7 56.2 - 67.1   59.7 53.5 - 65.8   73.6 60.3 - 87.0   56.7 49.2 - 64.2   67.7 60.1 - 75.3 
  5 60.1 54.5 - 65.7   58.5 52.3 - 64.8   69.1 54.0 - 84.2   54.7 46.9 - 62.5   66.7 58.8 - 74.5 
1-4 years 1 98.4 98.0 - 98.7 98.3 98.0 - 98.7 98.6 97.5 - 99.8 98.3 97.8 - 98.8 98.5 98.0 - 99.0 
3 96.1 95.5 - 96.7 96.2 95.6 - 96.8 93.6 90.8 - 96.3 95.8 95.0 - 96.6 96.5 95.6 - 97.3 
5 94.5 93.7 - 95.3 94.7 93.8 - 95.6 89.8 85.8 - 93.8 93.7 92.5 - 94.8 95.5 94.4 - 96.6 
5-9 years 1 97.0 96.4 - 97.6   97.2 96.6 - 97.8   97.3 95.4 - 99.1   97.3 96.5 - 98.0   96.6 95.6 - 97.5 
  3 93.1 92.1 - 94.1   93.6 92.5 - 94.6   92.0 88.4 - 95.5   92.6 91.2 - 94.0   93.9 92.5 - 95.3 
  5 90.4 89.0 - 91.8   91.1 89.7 - 92.5   87.8 82.5 - 93.1   89.7 87.8 - 91.6   91.3 89.4 - 93.3 
10-14 years 1 92.9 91.8 - 94.0 92.9 91.7 - 94.1 91.1 87.6 - 94.5 93.2 91.8 - 94.6 92.4 90.6 - 94.2 
3 84.9 83.2 - 86.6 86.1 84.3 - 87.9 76.8 71.1 - 82.5 84.7 82.4 - 86.9 85.3 82.7 - 87.9 
5 81.5 79.4 - 83.6 82.0 79.7 - 84.4 75.6 69.4 - 81.8 81.2 78.4 - 84.0 81.8 78.6 - 85.0 
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Table 1 – Acute lymphoblastic leukemia: number of children (0-14 years) diagnosed 2001-2009 and included in survival analyses, with data quality indicators, by US state and race
No. % No. % No. % No. % No. % No. % No. % No. % No. %
Alabama 260 100.0 202 77.7 54 20.8 255 98.1 198 98.0 53 98.1 0 0.0 0 0.0 0 0.0
Alaska 55 100.0 37 67.3 1 1.8 55 100.0 37 100.0 1 100.0 0 0.0 0 0.0 0 0.0
California 3,309 100.0 2,819 85.2 130 3.9 3,299 99.7 2,811 99.7 128 98.5 578 17.5 489 17.3 17 13.1
Colorado 384 100.0 354 92.2 5 1.3 381 99.2 351 99.2 5 100.0 0 0.0 0 0.0 0 0.0
Connecticut 261 100.0 243 93.1 9 3.4 253 96.9 236 97.1 9 100.0 41 15.7 37 15.2 0 0.0
Delaware 52 100.0 39 75.0 10 19.2 50 96.2 38 97.4 10 100.0 0 0.0 0 0.0 0 0.0
Florida 1,096 100.0 908 82.8 137 12.5 1,095 99.9 907 99.9 137 100.0 0 0.0 0 0.0 0 0.0
Georgia 604 100.0 439 72.7 137 22.7 594 98.3 433 98.6 134 97.8 34 5.6 25 5.7 7 5.1
Hawaii 91 100.0 17 18.7 4 4.4 90 98.9 16 94.1 4 100.0 43 47.3 5 29.4 2 50.0
Idaho 113 100.0 112 99.1 0 0.0 110 97.3 109 97.3 - - 0 0.0 0 0.0 - -
Iowa 198 100.0 188 94.9 7 3.5 197 99.5 187 99.5 7 100.0 23 11.6 22 11.7 1 14.3
Kentucky 264 100.0 239 90.5 19 7.2 257 97.3 233 97.5 19 100.0 32 12.1 27 11.3 3 15.8
Louisiana 255 100.0 181 71.0 68 26.7 253 99.2 180 99.4 67 98.5 65 25.5 50 27.6 12 17.6
Maryland 185 100.0 143 77.3 34 18.4 148 80.0 112 78.3 31 91.2 0 0.0 0 0.0 0 0.0
Massachusetts 472 100.0 423 89.6 30 6.4 472 100.0 423 100.0 30 100.0 0 0.0 0 0.0 0 0.0
Michigan 674 100.0 564 83.7 64 9.5 663 98.4 557 98.8 61 95.3 0 0.0 0 0.0 0 0.0
Mississippi 137 100.0 87 63.5 48 35.0 133 97.1 85 97.7 46 95.8 0 0.0 0 0.0 0 0.0
Montana 62 100.0 54 87.1 0 0.0 61 98.4 53 98.1 - - 29 46.8 25 46.3 - -
Nebraska 143 100.0 130 90.9 9 6.3 141 98.6 128 98.5 9 100.0 0 0.0 0 0.0 0 0.0
New Hampshire 103 100.0 102 99.0 0 0.0 103 100.0 102 100.0 - - 0 0.0 0 0.0 - -
New Jersey 653 100.0 519 79.5 80 12.3 634 97.1 508 97.9 76 95.0 52 8.0 38 7.3 6 7.5
New Mexico 182 100.0 160 87.9 0 0.0 180 98.9 158 98.8 - - 43 23.6 40 25.0 - -
New York 1,324 100.0 1,048 79.2 159 12.0 1,300 98.2 1,031 98.4 155 97.5 0 0.0 0 0.0 0 0.0
North Carolina 592 100.0 467 78.9 87 14.7 588 99.3 464 99.4 86 98.9 0 0.0 0 0.0 0 0.0
Ohio 726 100.0 639 88.0 58 8.0 716 98.6 630 98.6 57 98.3 0 0.0 0 0.0 0 0.0
Oklahoma 268 100.0 197 73.5 12 4.5 264 98.5 193 98.0 12 100.0 0 0.0 0 0.0 0 0.0
Oregon 293 100.0 254 86.7 8 2.7 293 100.0 254 100.0 8 100.0 0 0.0 0 0.0 0 0.0
Pennsylvania 830 100.0 707 85.2 80 9.6 824 99.3 702 99.3 80 100.0 0 0.0 0 0.0 0 0.0
Rhode Island 69 100.0 66 95.7 2 2.9 69 100.0 66 100.0 2 100.0 0 0.0 0 0.0 0 0.0
South Carolina 235 100.0 182 77.4 47 20.0 233 99.1 180 98.9 47 100.0 0 0.0 0 0.0 0 0.0
Tennessee 331 100.0 254 76.7 58 17.5 329 99.4 253 99.6 57 98.3 0 0.0 0 0.0 0 0.0
Texas 2,114 100.0 1,852 87.6 149 7.0 2,081 98.4 1,822 98.4 147 98.7 0 0.0 0 0.0 0 0.0
Utah 226 100.0 217 96.0 2 0.9 226 100.0 217 100.0 2 100.0 27 11.9 27 12.4 0 0.0
Washington 417 100.0 343 82.3 25 6.0 414 99.3 342 99.7 25 100.0 31 7.4 26 7.6 4 16.0
West Virginia 97 100.0 91 93.8 3 3.1 94 96.9 88 96.7 3 100.0 0 0.0 0 0.0 0 0.0
Wisconsin 392 100.0 334 85.2 22 5.6 350 89.3 297 88.9 19 86.4 0 0.0 0 0.0 0 0.0
Wyoming 33 100.0 29 87.9 2 6.1 30 90.9 26 89.7 2 100.0 0 0.0 0 0.0 0 0.0
Total 17,500 100.0 14,640 83.7 1,560 8.9 17,235 98.5 14,427 98.5 1,529 98.0 998 5.7 811 5.5 52 3.3
Black
Number of patients Morphologically verified Lost to follow-up
    All White Black     All White Black     All White
Table 1 – Data quality indicators by state and race - ALL in children 1 of 1 Produced   29 April 2016
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Years NS NS NS NS NS NS 
UNITED STATES
1 95.3 94.6 - 95.9 95.3 94.6 - 96.0 95.0 93.0 - 97.1 95.7 95.3 - 96.1 95.7 95.3 - 96.2 95.5 94.1 - 96.9
3 89.7 88.8 - 90.7 89.8 88.8 - 90.9 87.5 84.3 - 90.6 90.7 90.0 - 91.4 91.2 90.5 - 92.0 86.7 84.2 - 89.1
5 86.4 85.3 - 87.4 86.6 85.5 - 87.7 83.8 80.3 - 87.3 88.1 87.2 - 88.9 88.6 87.6 - 89.5 83.6 80.6 - 86.6
NORTHEAST
New England
Connecticut 1 97.7 94.4 - 100.0 97.4 93.7 - 100.0 - 98.9 97.6 - 100.0 98.8 97.5 - 100.0 -
(SEER) 3 93.0 87.3 - 98.6 91.9 85.5 - 98.3 - 93.8 89.1 - 98.4 93.4 88.5 - 98.3 -
5 91.4 85.3 - 97.5 91.9 85.5 - 98.3 - 89.5 82.3 - 96.7 89.0 81.5 - 96.5 -
Massachusetts 1 96.6 93.2 - 99.9 96.1 92.2 - 100.0 100.0 - 96.4 94.1 - 98.6 96.8 94.4 - 99.1 95.0 85.7 - 100.0
(NPCR) 3 88.3 82.1 - 94.6 89.2 82.6 - 95.7 80.1 56.7 - 100.0 92.5 88.9 - 96.1 93.4 89.8 - 96.9 88.3 73.2 - 100.0
5 82.0 74.6 - 89.4 84.4 76.9 - 91.9 60.2 31.7 - 88.6 92.6 89.0 - 96.2 93.4 89.8 - 97.0 88.3 73.2 - 100.0
New Hampshire 1 100.0 - 100.0 - - 91.4 84.7 - 98.1 91.3 84.6 - 98.0 -
(NPCR) 3 100.0 - 100.0 - - 85.2 76.0 - 94.4 85.1 75.8 - 94.3 -
5 96.7 90.1 - 100.0 96.7 90.1 - 100.0 - 85.2 76.0 - 94.5 85.1 75.8 - 94.4 -
Rhode Island 1 100.0 100.0 - 100.0 100.0 100.0 - 100.0 - 98.6 95.8 - 100.0 98.6 95.8 - 100.0 -
(NPCR) 3 100.0 100.0 - 100.0 100.0 100.0 - 100.0 - 98.6 95.9 - 100.0 98.6 95.9 - 100.0 -
5 89.5 81.0 - 98.1 88.9 79.9 - 98.0 - 98.6 95.9 - 100.0 98.6 95.9 - 100.0 -
Mid Atlantic
New Jersey 1 95.2 92.1 - 98.3 95.8 92.5 - 99.2 89.3 78.1 - 100.0 95.1 92.7 - 97.5 95.3 92.5 - 98.0 95.2 89.4 - 100.0
(NPCR/SEER) 3 89.2 84.8 - 93.6 90.1 85.0 - 95.1 78.7 63.8 - 93.6 91.8 88.6 - 94.9 92.0 88.6 - 95.5 91.2 82.7 - 99.7
5 87.3 82.5 - 92.1 88.5 83.1 - 93.8 78.7 63.8 - 93.6 90.1 86.4 - 93.9 90.7 86.5 - 94.9 85.3 74.1 - 96.5
New York 1 94.9 92.5 - 97.4 95.0 92.3 - 97.7 95.4 89.3 - 100.0 95.9 94.3 - 97.5 95.7 93.8 - 97.5 97.9 95.0 - 100.0
(NPCR) 3 89.0 85.5 - 92.4 89.1 85.2 - 92.9 87.4 78.3 - 96.5 91.5 89.0 - 93.9 91.4 88.7 - 94.2 91.2 84.8 - 97.5
5 84.6 80.7 - 88.5 84.6 80.3 - 89.0 82.3 72.3 - 92.2 89.7 87.0 - 92.5 89.7 86.6 - 92.9 87.8 80.1 - 95.4
Pennsylvania 1 95.0 92.0 - 98.0 93.9 90.3 - 97.5 100.0 - 93.0 90.3 - 95.7 93.5 90.6 - 96.3 90.2 82.7 - 97.6
(NPCR) 3 91.0 87.2 - 94.9 90.7 86.4 - 94.9 92.2 81.8 - 100.0 88.2 84.7 - 91.7 89.4 85.7 - 93.0 79.2 68.4 - 90.1
5 87.0 82.6 - 91.5 85.8 80.8 - 90.8 92.2 81.8 - 100.0 87.8 84.1 - 91.4 88.9 85.0 - 92.7 79.2 68.4 - 90.1
SOUTH
South Atlantic
Delaware 1 90.0 77.2 - 100.0 86.7 70.1 - 100.0 - 97.8 93.7 - 100.0 95.5 87.0 - 100.0 -
(NPCR) 3 85.0 69.8 - 100.0 86.7 70.1 - 100.0 - 95.0 88.7 - 100.0 90.2 77.5 - 100.0 -
5 85.0 69.8 - 100.0 86.7 70.1 - 100.0 - 81.7 65.6 - 97.8 90.2 77.5 - 100.0 -
Florida 1 96.7 94.3 - 99.1 96.7 94.0 - 99.3 100.0 - 96.5 94.9 - 98.2 96.5 94.7 - 98.4 95.8 91.4 - 100.0
(NPCR) 3 90.7 87.0 - 94.5 89.6 85.3 - 93.9 97.5 92.3 - 100.0 91.8 89.1 - 94.5 92.4 89.5 - 95.3 86.3 78.4 - 94.2
5 87.5 83.3 - 91.7 86.4 81.6 - 91.2 94.9 87.7 - 100.0 88.1 84.1 - 92.0 89.6 85.5 - 93.7 79.6 69.5 - 89.7
Georgia 1 96.4 93.3 - 99.4 96.3 92.4 - 100.0 94.0 86.0 - 100.0 96.3 94.1 - 98.5 96.8 94.2 - 99.3 94.5 89.7 - 99.3
(NPCR/SEER) 3 94.5 90.9 - 98.1 94.0 89.4 - 98.5 94.0 86.0 - 100.0 89.4 85.4 - 93.4 91.7 87.5 - 96.0 81.7 72.5 - 90.8
5 92.4 88.1 - 96.8 91.0 85.3 - 96.7 94.0 86.0 - 100.0 87.9 83.5 - 92.4 89.8 84.8 - 94.8 81.7 72.6 - 90.9
Maryland 1 70.5 57.2 - 83.8 65.9 51.6 - 80.2 - 96.3 92.5 - 100.0 96.7 92.7 - 100.0 95.5 87.0 - 100.0
(NPCR) 3 64.4 50.6 - 78.2 61.0 46.3 - 75.7 - 92.8 87.0 - 98.7 94.9 89.6 - 100.0 90.3 77.6 - 100.0
5 61.4 47.4 - 75.3 58.6 43.8 - 73.4 - 87.1 78.2 - 96.1 88.6 77.7 - 99.6 72.3 42.3 - 100.0
North Carolina 1 96.6 93.9 - 99.4 97.7 95.1 - 100.0 96.5 89.7 - 100.0 95.9 93.3 - 98.5 96.9 94.3 - 99.6 91.9 84.9 - 99.0
(NPCR) 3 92.1 88.0 - 96.2 95.2 91.6 - 98.7 82.3 68.3 - 96.2 90.1 86.0 - 94.1 93.1 89.3 - 96.9 78.9 67.8 - 90.1
5 89.1 84.3 - 93.9 92.7 88.2 - 97.2 75.2 59.5 - 90.9 85.4 79.9 - 90.9 88.5 82.5 - 94.4 72.7 58.1 - 87.4
South Carolina 1 99.1 97.1 - 100.0 98.9 96.9 - 100.0 100.0 - 93.8 89.4 - 98.3 96.2 92.8 - 99.6 91.0 81.3 - 100.0
(NPCR) 3 95.2 89.8 - 100.0 95.4 90.9 - 99.8 91.0 74.8 - 100.0 88.4 82.3 - 94.4 92.3 87.4 - 97.3 79.9 65.4 - 94.4
5 92.8 86.2 - 99.4 91.8 85.9 - 97.6 91.0 74.8 - 100.0 87.2 80.8 - 93.6 90.9 85.3 - 96.5 79.9 65.5 - 94.4
West Virginia 1 95.7 87.5 - 100.0 95.3 86.4 - 100.0 - 95.8 92.0 - 99.7 97.8 94.8 - 100.0 -
(NPCR) 3 91.4 80.1 - 100.0 90.6 78.3 - 100.0 - 91.6 85.6 - 97.6 93.4 87.8 - 99.1 -
5 91.4 80.1 - 100.0 90.6 78.3 - 100.0 - 87.1 79.0 - 95.2 88.8 80.8 - 96.8 -
East South Central
Alabama 1 96.8 92.3 - 100.0 97.6 92.6 - 100.0 93.4 81.2 - 100.0 92.4 87.8 - 96.9 91.1 85.5 - 96.6 96.5 91.9 - 100.0
(NPCR) 3 89.6 82.5 - 96.7 96.8 91.7 - 100.0 66.7 43.8 - 89.6 86.7 80.5 - 92.9 89.2 83.1 - 95.3 77.9 65.0 - 90.9
5 87.2 79.4 - 94.9 93.8 87.4 - 100.0 66.7 43.8 - 89.6 85.6 79.0 - 92.1 87.8 81.1 - 94.5 78.0 65.0 - 90.9
Kentucky 1 91.4 83.1 - 99.6 96.0 92.1 - 99.9 - 95.7 90.9 - 100.0 95.1 89.8 - 100.0 100.0 100.0 - 100.0
(NPCR/SEER) 3 86.0 76.3 - 95.7 92.0 86.6 - 97.4 - 90.2 83.5 - 96.8 89.9 82.8 - 97.1 85.8 61.7 - 100.0
5 85.3 75.4 - 95.1 91.1 85.5 - 96.8 - 82.4 73.3 - 91.6 81.9 72.4 - 91.5 85.9 61.7 - 100.0
Mississippi 1 95.3 86.4 - 100.0 90.9 74.7 - 100.0 - 95.4 90.9 - 99.9 96.6 91.6 - 100.0 94.8 87.6 - 100.0
(NPCR) 3 95.3 86.4 - 100.0 90.9 74.7 - 100.0 - 82.9 74.3 - 91.4 78.0 66.1 - 89.9 87.3 75.3 - 99.2
5 95.3 86.4 - 100.0 90.9 74.7 - 100.0 - 83.0 74.4 - 91.5 78.1 66.2 - 90.0 87.3 75.4 - 99.3
Tennessee 1 100.0 100.0 - 100.0 100.0 100.0 - 100.0 - 95.5 92.5 - 98.6 94.8 90.9 - 98.7 97.2 92.2 - 100.0
(NPCR) 3 100.0 100.0 - 100.0 100.0 100.0 - 100.0 - 92.1 88.2 - 96.1 93.5 89.2 - 97.8 86.6 77.0 - 96.2
5 100.0 100.0 - 100.0 100.0 100.0 - 100.0 - 92.2 88.3 - 96.1 93.5 89.2 - 97.8 86.6 77.0 - 96.2
West South Central
Louisiana 1 94.0 88.6 - 99.3 97.1 92.6 - 100.0 88.1 75.6 - 100.0 96.5 93.6 - 99.4 96.5 93.1 - 100.0 96.0 90.9 - 100.0
(NPCR/SEER) 3 92.5 86.9 - 98.2 96.1 91.2 - 100.0 84.2 70.1 - 98.3 87.3 80.6 - 93.9 86.8 78.7 - 94.9 89.4 81.5 - 97.4
5 90.1 83.4 - 96.7 92.1 84.9 - 99.3 84.3 70.2 - 98.4 87.4 80.7 - 94.0 86.9 78.8 - 94.9 89.5 81.6 - 97.5
Oklahoma 1 94.9 89.7 - 100.0 93.2 86.5 - 100.0 - 96.1 92.6 - 99.5 99.0 97.5 - 100.0 -
(NPCR) 3 88.9 81.6 - 96.1 87.0 78.2 - 95.9 - 84.1 75.9 - 92.2 89.1 80.5 - 97.7 -
5 85.6 77.4 - 93.9 85.5 76.2 - 94.8 - 83.4 75.1 - 91.6 88.2 79.4 - 97.0 -
Texas 1 94.4 92.4 - 96.5 94.3 92.0 - 96.6 94.4 87.4 - 100.0 94.5 93.0 - 95.9 94.1 92.6 - 95.7 95.6 90.8 - 100.0
(NPCR) 3 87.4 84.4 - 90.4 86.7 83.4 - 90.0 91.7 83.3 - 100.0 88.7 86.6 - 90.9 88.7 86.4 - 91.0 89.6 81.8 - 97.4
5 83.2 79.8 - 86.5 82.5 78.8 - 86.1 86.2 75.9 - 96.5 85.9 83.2 - 88.6 85.7 82.8 - 88.6 86.7 77.4 - 96.1
2001-2003 2004-2009
All races White Black All races White Black
95% CI 95% CI 95% CI 95% CI 95% CI 95% CI
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MIDWEST
East North Central
Michigan 1 96.0 92.9 - 99.0 96.5 93.5 - 99.6 94.4 84.2 - 100.0 95.3 93.0 - 97.6 94.9 92.2 - 97.6 98.3 95.0 - 100.0
(NPCR) 3 92.8 88.9 - 96.7 94.4 90.6 - 98.2 89.0 74.8 - 100.0 88.7 84.6 - 92.8 88.9 84.3 - 93.4 82.3 68.7 - 96.0
5 88.7 83.9 - 93.5 90.6 85.7 - 95.5 83.5 66.7 - 100.0 87.8 83.5 - 92.1 87.7 82.8 - 92.5 82.4 68.8 - 96.1
Ohio 1 93.7 90.3 - 97.1 93.2 89.4 - 97.1 100.0 - 97.5 95.7 - 99.3 97.9 96.1 - 99.7 96.1 91.1 - 100.0
(NPCR) 3 89.0 84.4 - 93.6 88.7 83.6 - 93.7 94.5 84.2 - 100.0 93.7 90.8 - 96.7 94.9 91.9 - 97.9 88.3 80.0 - 96.5
5 86.7 81.7 - 91.7 86.0 80.5 - 91.5 94.5 84.2 - 100.0 90.3 86.2 - 94.5 90.0 84.9 - 95.1 88.4 80.1 - 96.6
Wisconsin 1 96.0 91.9 - 100.0 96.8 93.0 - 100.0 - 98.4 97.2 - 99.6 98.2 96.8 - 99.5 100.0 100.0 - 100.0
(NPCR) 3 88.6 81.9 - 95.2 91.0 84.5 - 97.6 - 92.9 88.8 - 97.0 91.6 86.7 - 96.4 100.0 100.0 - 100.0
5 88.6 81.9 - 95.2 91.0 84.5 - 97.6 - 89.6 83.5 - 95.7 87.7 80.6 - 94.7 100.0 100.0 - 100.0
West North Central
Iowa 1 100.0 100.0 - 100.0 100.0 100.0 - 100.0 - 93.9 88.8 - 99.1 95.0 90.1 - 99.9 -
(SEER) 3 94.0 86.7 - 100.0 94.0 86.7 - 100.0 - 89.1 81.1 - 97.1 90.0 81.9 - 98.1 -
5 90.3 81.8 - 98.7 89.8 81.1 - 98.5 - 89.1 81.1 - 97.1 90.0 81.9 - 98.1 -
Nebraska 1 98.2 95.8 - 100.0 100.0 100.0 - 100.0 - 95.5 89.2 - 100.0 95.0 88.1 - 100.0 -
(NPCR) 3 96.5 93.1 - 99.9 98.0 95.2 - 100.0 - 90.7 81.9 - 99.5 89.7 80.1 - 99.3 -
5 94.0 88.2 - 99.7 95.3 89.5 - 100.0 - 88.6 79.0 - 98.2 87.4 77.0 - 97.9 -
WEST
Mountain
Colorado 1 91.2 85.2 - 97.1 91.0 85.0 - 97.0 - 95.7 92.5 - 98.8 95.4 92.1 - 98.7 -
(NPCR) 3 84.4 77.1 - 91.7 84.2 76.8 - 91.5 - 93.4 89.2 - 97.7 93.1 88.8 - 97.4 -
5 82.9 75.4 - 90.3 82.7 75.1 - 90.2 - 93.5 89.3 - 97.7 93.2 88.8 - 97.5 -
Idaho 1 97.1 91.5 - 100.0 97.1 91.5 - 100.0 - 95.0 89.8 - 100.0 95.0 89.8 - 100.0 -
(NPCR) 3 91.3 81.9 - 100.0 91.3 81.9 - 100.0 - 95.0 89.8 - 100.0 95.0 89.8 - 100.0 -
5 88.4 77.7 - 99.1 88.4 77.7 - 99.1 - 95.1 89.9 - 100.0 95.1 89.9 - 100.0 -
Montana 1 94.1 83.3 - 100.0 92.3 78.4 - 100.0 - 92.7 86.0 - 99.4 92.1 85.0 - 99.2 -
(NPCR) 3 94.2 83.4 - 100.0 92.4 78.5 - 100.0 - 89.5 81.6 - 97.4 88.7 80.4 - 96.9 -
5 88.0 72.7 - 100.0 84.1 64.5 - 100.0 - 89.6 81.7 - 97.5 88.8 80.5 - 97.0 -
New Mexico 1 100.0 100.0 - 100.0 100.0 100.0 - 100.0 - 96.5 93.4 - 99.6 96.8 93.6 - 100.0 -
(SEER) 3 97.5 94.2 - 100.0 96.9 92.9 - 100.0 - 86.5 77.8 - 95.3 89.4 81.9 - 97.0 -
5 94.5 89.4 - 99.7 93.6 87.8 - 99.5 - 86.6 77.8 - 95.4 89.5 81.9 - 97.1 -
Utah 1 99.1 97.4 - 100.0 99.1 97.4 - 100.0 - 97.6 94.9 - 100.0 98.6 96.5 - 100.0 -
(SEER) 3 98.2 95.8 - 100.0 98.2 95.8 - 100.0 - 95.8 92.2 - 99.5 96.7 93.4 - 100.0 -
5 96.5 93.2 - 99.7 96.5 93.2 - 99.7 - 95.9 92.2 - 99.6 96.8 93.4 - 100.0 -
Wyoming 1 - - - 100.0 100.0 - 100.0 100.0 100.0 - 100.0 -
(NPCR) 3 - - - 100.0 100.0 - 100.0 100.0 100.0 - 100.0 -
5 - - - 100.0 100.0 - 100.0 100.0 100.0 - 100.0 -
Pacific
Alaska 1 100.0 - - - 91.8 83.0 - 100.0 92.6 82.9 - 100.0 -
(NPCR) 3 93.9 82.3 - 100.0 - - 88.0 77.0 - 99.1 92.6 82.9 - 100.0 -
5 93.9 82.3 - 100.0 - - 88.1 77.0 - 99.2 92.7 82.9 - 100.0 -
California 1 95.0 93.4 - 96.6 95.3 93.6 - 97.0 91.7 84.9 - 98.5 95.9 94.9 - 96.8 95.6 94.6 - 96.7 98.7 96.3 - 100.0
(NPCR/SEER) 3 87.2 84.9 - 89.6 87.1 84.6 - 89.7 79.8 67.7 - 91.8 90.6 89.0 - 92.1 90.6 88.9 - 92.3 89.8 82.3 - 97.2
5 83.4 80.8 - 85.9 84.0 81.2 - 86.7 76.5 63.7 - 89.3 86.0 83.7 - 88.4 85.9 83.3 - 88.4 87.7 79.3 - 96.0
Hawaii 1 100.0 100.0 - 100.0 - - 96.2 92.1 - 100.0 100.0 100.0 - 100.0 -
(SEER) 3 97.0 91.6 - 100.0 - - 94.4 89.2 - 99.5 100.0 100.0 - 100.0 -
5 94.0 87.4 - 100.0 - - 94.4 89.2 - 99.5 100.0 100.0 - 100.0 -
Oregon 1 93.2 87.3 - 99.1 92.1 85.3 - 98.8 - 98.1 95.8 - 100.0 98.1 95.5 - 100.0 -
(NPCR) 3 86.3 78.8 - 93.8 84.0 75.5 - 92.6 - 92.8 87.7 - 97.9 94.7 90.1 - 99.4 -
5 83.4 75.4 - 91.4 83.3 74.7 - 91.9 - 88.8 81.9 - 95.6 90.7 83.8 - 97.7 -
Washington 1 96.6 93.4 - 99.8 96.7 93.2 - 100.0 - 97.1 94.8 - 99.3 97.3 94.8 - 99.9 100.0 100.0 - 100.0
(NPCR) 3 92.9 88.4 - 97.4 92.1 86.8 - 97.5 - 95.7 93.1 - 98.4 95.7 92.7 - 98.7 100.0 100.0 - 100.0
5 88.7 83.0 - 94.5 88.2 81.6 - 94.9 - 92.3 88.1 - 96.5 91.8 87.0 - 96.6 100.0 100.0 - 100.0
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